期刊文献+

PARP-1及其抑制剂在卵巢癌治疗中的研究进展 被引量:2

Research Progress of PARP-1 and Its Inhibitors in Treatment of Ovarian Cancer
下载PDF
导出
摘要 卵巢癌早期症状隐匿,临床发现时多属于疾病晚期,其死亡率在妇科恶性肿瘤中最高。聚二磷酸腺苷核糖聚合酶-1(PARP-1)在卵巢癌中高表达,它与卵巢癌的发展、侵袭和预后有密切联系。PARP-1抑制剂可与存在同源重组修复缺陷的肿瘤细胞发生协同致死作用,但不会杀伤正常细胞,若抑制PARP-1介导的单链DNA修复将导致DNA开始半保留复制,随后造成双链DNA损伤,从而导致细胞死亡。因此,PARP-1成为目前卵巢癌靶向治疗的热点。未来,应进一步研究PARP-1及其抑制剂的作用机制和它们的代表药物在卵巢癌中的靶向治疗。 Ovarian cancer has concealed early symptoms,and most of the cases are found in late stage,contributing to its highest mortality among gynecologic malignancies.Poly(ADP-ribose)polymerase-1(PARP-1)is highly expressed in ovarian cancer,and it is closely related to the development,invasion and prognosis.PARP-1 inhibitors can be associated with tumor cells with homologous recombination deficiency to generate synergistic lethal effect,but does not kill normal cells.Inhibition of PARP-1 mediated single-stranded DNA repair will lead to DNA semi-reserved replication,which subsequently causes double-stranded DNA damage,leading to cell death.Therefore,PARP-1 has become a hotspot in current ovarian cancer targeted therapy.In the future,the mechanisms of PARP-1 and its inhibitors and the targeted therapy of their representative drugs in ovarian cancer should be further studied.
作者 杨婧 郑洪 谭娜 YANG Jing;ZHENG Hong;TAN Na(Department of Pathology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)
出处 《医学综述》 2019年第22期4427-4432,共6页 Medical Recapitulate
基金 贵州省科技合作计划项目(黔科合LH字〔2015〕7455号) 遵义市科技计划课题(遵市科合社字〔2018〕85)
关键词 卵巢癌 聚腺苷酸二磷酸核糖聚合酶-1 聚腺苷酸二磷酸核糖聚合酶抑制剂 Ovarian cancer Poly(ADP-ribose)polymerase-1 Poly(ADP-ribose)polymerase inhibitor
  • 相关文献

参考文献3

二级参考文献17

  • 1Hiroaki Itamochi.Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action[J].World Journal of Biological Chemistry,2010,1(7):209-220. 被引量:14
  • 2KARST AM,DRAPKIN R.The new face of ovarian cancer modeling:better prospects for detection and treatment.F1000Med Rep,2011(3):22.doi:10.3410/M3-22.
  • 3ARGENTO M,HOFFMAN P,GAUCHEZ AS.Ovarian cancer detection and treatment:current situation and future prospects.Anticancer Res,2008,28(5B):3135-3138.
  • 4FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012.Int J Cancer,2015,136(5):E359-E386.
  • 5GUBBELS JA,CLAUSSEN N,KAPUR AK,et al.The detection,treatment,and biology of epithelial ovarian cancer.J Ovarian Res,2010(3):8.doi:10.1186/1757-2215-3-8.
  • 6HAN LY,KIPPS E,KAYE SB.Current treatment and clinical trials in ovarian cancer.Expert Opin Investigl Drugs,2010,19(4):521-534.
  • 7MOSS C,KAYE SB.Ovarian cancer:progress and continuing controversies in management.Eur J Cancer,2002,38(13):1701-1707.
  • 8ROSELL R,LORD RV,TARON M,et al.DNA repair and cisplatin resistance in non-small-cell lungcancer.Lung Cancer,2002,38(3):217-227.
  • 9JORDAN P,CARMO-FONSECA M.Molecular mechanisms involved in cisplatin cytotoxicity.Cell Mol Life Sci,2000;57(8-9):1229-1235.
  • 10BERNSTEIN C,BERNSTEIN H,PAYNE CM,et al.DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways:fail-safe protection against carcinogenesis.Mutat Res,2002,511(2):145-178.

共引文献14

同被引文献23

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部